Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived  Natural Killer Cells Paris Stock Exchange:ALCLS
(MENAFN - GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic 'off-the-shelf' gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collab...